Table 3:

Treatment characteristics by individual patient

Patient	Regimen	Treatment Time (days)	Discontinuation Reason	Type of Progression	TTF (days)	PFS (days)	Lines before Treatment	Lines after Treatment
1	PD-1/PD-L1	153	POD	radiographic	167	151	2	1
2	PD-1/PD-L1+CTLA-4	14	POD	clinical/radiographic	36	21	7	0
3	PD-1/PD-L1+CTLA-4	329	POD	radiographic	358	336	4	4
4	PD-1/PD-L1+CTLA-4	56	POD	clinical/radiographic	106	81	4	2
5	PD-1/PD-L1+ targeted therapy	28	POD, adverse event (autoimmune neuropathy)	clinical, radiographic	60	43	3	0
6	PD-1/PD-L1	28	POD	clinical, radiographic	53	49	3	1
7	PD-1/PD-L1	49	POD	radiographic	74	50	2	2
8	PD-1/PD-L1+ targeted therapy	104	POD	radiographic	146	119	3	1
9	PD-1/PD-L1+CTLA-4	14	POD	clinical, radiographic	78	45	3	0
10	PD-1/PD-L1+CTLA-4	574	adverse event (acute liver injury)	N/A	1568	1538	1	2
10	PD-1/PD-L1+CTLA-4	21	adverse event	N/A	157a	N/A	3	N/A
11	PD-1/PD-L1	393	POD	radiographic/biopsy-proven	402	387	7	2
12	PD-1/PD-L1+CTLA-4	383	N/A	N/A	383a	N/A	2	N/A
13	PD-1/PD-L1	54	POD	radiographic	62	55	2	6
14	PD-1/PD-L1+CTLA-4	63	POD	clinical/radiographic	99	80	1	0
15	PD-1/PD-L1+ targeted therapy	15	POD	clinical/radiographic	27	21	2	0
16	PD-1/PD-L1+ targeted therapy	113	POD	radiographic	134	123	2	1

TTF: time to treatment failure; PFS: progression free survival; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1; CTLA-4: cytotoxic T-lymphocyte–associated antigen 4; POD: progression of disease

^athese patients continue to have an ongoing response to ICB therapy and remain disease free at the time of database closure. Their duration of response between start of ICB and time of data censoring is indicated here.